According to investigators, there is no validated PSA-based endpoint to compare oncologic outcomes after radical prostatectomy and radiation therapy for localized prostate cancer.

Auron will present data highlighting the activity of AUTX-703, its oral, potent and selective degrader targeting KAT2A/B in cell lines and patient derived organoid models (PDXO) of neuroendocrine ...

According to the American Cancer Society, approximately 1 in 8 men in the U.S. will be diagnosed with prostate cancer during their lifetime.

Thursday is Prostate Cancer Awareness Day at the State House, and lawmakers are speaking out about the importance of early and frequent screening.

A new at-home saliva test could help identify men with a high risk of prostate cancer more accurately than blood tests, leading to earlier diagnosis and more successful treatment. Prostate cancer ...

Abstract Highlights ORIC-944 is a potent, highly selective, orally bioavailable, allosteric inhibitor of PRC2 that demonstrates best-in-class drug properties, including potency, solubility, and ...

The research shows that germline and somatic variability work together to initiate and drive progression of prostate cancer. This discovery could one day help improve how doctors predict and treat ...